Leaders in Pharmaceutical Business Intelligence (LPBI) Group

3:30 pm – 4:20 pm LIVE Trends in Science Track: Immunotherapy – Oncology and Beyond @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Reporter: Aviva Lev-Ari, PhD, RN

 

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

#oncology#cancer #immunotherapies #Curis #Mersana #ImmunosanT

@MassBio@PharmaNews @BioWorld @bioitworld @cancer @BiotechNews @MersanaADC

Panelists:

• Mani Mohindru, Vice President of Corporate Strategy and Investor Relations, Curis, Inc.

1. Stimulate the immune response with small molecule vs large molecule antibodies PD1 PDL1 blog interferon taken to rat model for colon cancer, lung cancer

2. Cancer biomarkers, great results in subsets of patients, molecular signatures or genes in combination therapy

3. identify patients for best response

4. Small molecule easier to use in animal model

5. FDA very receptive to innovative approaches that quality of life is incorporated early on

6. Tumor Infiltrated Lymphocytes  (TIL) if a patient does not have enough of them — what  is the threshold in a dynamic time frame — cancer mutate continuously

7.

• Anna Protopapas, President & CEO, Mersana Therapeutics

1. Conjugate: Millenium licensed it outside the US

2. Mersana – payload onto the antibody, higher efficacy targets of low efficacy can be enhanced by the Mersana approach to conjugate which is very different than the one taken by Millenium /Takeda

3. selection of target, targeting tumors with low expressing Tumors

4. deliver of drug to tumor, stratify tumor expression level, efficacy -Tumors shrinkage of

5. fragments biospecific antibodies are delivering the drug

6. manufacture antibody payload antibody – it is a multi component process

7. efficacy in Cancer drugs is paramount

8. Compationate Progrma to make a drug from Phase III that passed till the approval one year – drugs made available to patients

• Leslie Williams, President & CEO, ImmusanT, Inc. Celliac Disease Diagnostics, pharmacogenomics

1. Vaccine space as a therapeutics induce immune tolerance not preventative. when gluten is injected, gene and access to gut by endoscopy, MOA known, genomics is known biomarker known

2. On Precision Medicine CD modifying the T cell assay all done in Humans, three peptides Phase II have signature to predict response, phase I – companion diagnostics used to be given the drugs, tool kit allows to monitor maintenance of tolerance

3. Celliac between autoimmune and allergy – introduce gluten during treatment and monitor tolerance

inte 4. Onset at 4 years old, diagnosis is at median age of 45

5. develop a simple blood based diagnostic. at present time diagnosis is done my biopsy

6. celiac a disease undiagnosed – of the 1% with the disease only 15% are diagnosed

7. right patient, right drug

Moderator:

• Philip G. Vanek,  General Manager for Cell Therapy Technologies, GE Healthcare LifeSciences

2013 – Science names Immunotherapy the Innovation of the Year

GE is interested in manufacturing, integration with patient data and process manufacturing